Phase II Study of 177 Lu-DOTATATE for Progressive Metastatic Pheochromocytomas and Paragangliomas: Interim Analysis of Efficacy, Safety, and Biomarkers
Journal of Clinical Oncology · 2025-10 · 43 (28) · 3102-3112
DOI: 10.1200/jco-25-00791 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, 2025-10. Verfasst von Frank I Lin und 19 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Imaging Branch, National Institutes of Health, National Cancer Institute, Center for Cancer Research, Bethesda, MD. Hauptthemen laut MEDLINE: Organometallic Compounds, Octreotide, Pheochromocytoma, Paraganglioma. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS.
Abstract (Originalsprache)
PURPOSE 177 Lu-DOTA(0)-Tyr(3)-octreotate ( 177 Lu-DOTATATE) is a somatostatin receptor (SSTR)-targeting radiopharmaceutical that shows promise for treating metastatic pheochromocytomas/paragangliomas (PPGLs), a rare SSTR-expressing tumor. METHODS In the first stage of this two-stage Simon phase II trial, 36 PPGL patients with RECIST 1.1 progression within 12 months were prospectively recruited into two genetic cohorts (succinate dehydrogenase [ SDHx ]–mutated v apparent sporadic, 18 per cohort) and treated with four cycles of 177 Lu-DOTATATE. The primary end point was progression-free survival (PFS) rate at 6 months (from initiation of treatment). Secondary end points included safety, overall survival (OS), response rate, imaging/serum biomarkers, and antihypertensive medication reduction. Computed tomography/magnetic resonance imaging (CT/MRIs) and positron emission tomography (PET)-CTs ( 68 Ga-DOTATATE and 18 F-labeled fluorodeoxyglucose) were obtained after two and four cycles, then every 3 (CT/MRIs) to 6 months (PET/CTs). Patients with systolic blood pressure (SBP) > 200 mmHg despite medical management were treated in the intensive care unit (ICU). RESULTS Six-month PFS rate for all patients was 0.861 (95% CI, 0.755 to 0.982), which was significantly lower ( P = .009) for SDHx at 0.72 (95% CI, 0.542 to 0.962) versus sporadic at 1.00 (95% CI, 1.0 to 1.0). Median PFS was 19.9 months (12.9 months SDHx v 24.3 months sporadic) and median OS was 51.7 months (31.2 months SDHx v not reached in sporadic). Best response was achieved on average 11.0 months after completing 177 Lu-DOTATATE. A 17% incidence of grade 3+ catecholamine release syndrome (CRS) was noted, which may benefit from preemptive ICU admission. Plasma chromogranin A and normetanephrine were the best tumor-marker surrogates and correlated well with changes in RECIST sum and total tumor lesion uptake on serial 68 Ga-DOTATATE PET-CT scans. CONCLUSION 177 Lu-DOTATATE demonstrated effectiveness and acceptable safety profile for progressive, metastatic PPGL. CRS may occur but can be mitigated through pretreatment with antihypertensives, and, when appropriate, intensified monitoring in the ICU with intravenous antihypertensives.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Molecular Imaging Branch, National Institutes of Health, National Cancer Institute, Center for Cancer Research, Bethesda, MD.
- Developmental Therapeutics Branch, National Institutes of Health, National Cancer Institute, Center for Cancer Research, Bethesda, MD.
- National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD.
- Division of Cancer Therapy and Diagnosis, Biometric Research Program, National Institutes of Health, National Cancer Institute, Bethesda, MD.
- Metabolic Diseases Branch, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
- Uniformed Services University of the Health Sciences, Bethesda, MD.
ORCID-Profile: Frank I Lin, Jaydira Del Rivero, Jorge A Carrasquillo, Abhishek Jha, Sara Talvacchio, Baris Turkbey, Liza Lindenberg, Yating Teng, Freddy E Escorcia, Karel Pacak
Förderung
- Intramural NIH HHS
Zitieren
APA
Lin, F. I., Del Rivero, J., Carrasquillo, J. A., Jha, A., Zou, J., Shamis, I., Talvacchio, S., Turkbey, B., Huang, E. P., Shih, J., Klubo-Gwiezdzinska, J., Mena, E., Lindenberg, L., Teng, Y., Escorcia, F. E., Chen, C., Herscovitch, P., Millo, C., Choyke, P. L., & Pacak, K. (2025). Phase II Study of 177 Lu-DOTATATE for Progressive Metastatic Pheochromocytomas and Paragangliomas: Interim Analysis of Efficacy, Safety, and Biomarkers. Journal of Clinical Oncology, 43(28), 3102-3112. https://doi.org/10.1200/jco-25-00791
Vancouver
Lin FI, Del Rivero J, Carrasquillo JA, Jha A, Zou J, Shamis I, et al. Phase II Study of 177 Lu-DOTATATE for Progressive Metastatic Pheochromocytomas and Paragangliomas: Interim Analysis of Efficacy, Safety, and Biomarkers. Journal of Clinical Oncology. 2025;43(28):3102-3112. doi:10.1200/jco-25-00791
BibTeX
@article{Lin2025,
author = {Lin, Frank I and Del Rivero, Jaydira and Carrasquillo, Jorge A and Jha, Abhishek and Zou, Joy and Shamis, Inna and Talvacchio, Sara and Turkbey, Baris and Huang, Erich P and Shih, Joanna and Klubo-Gwiezdzinska, Joanna and Mena, Esther and Lindenberg, Liza and Teng, Yating and Escorcia, Freddy E and Chen, Clara and Herscovitch, Peter and Millo, Corina and Choyke, Peter L and Pacak, Karel},
title = {Phase II Study of 177 Lu-DOTATATE for Progressive Metastatic Pheochromocytomas and Paragangliomas: Interim Analysis of Efficacy, Safety, and Biomarkers},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {28},
pages = {3102--3112},
doi = {10.1200/jco-25-00791}
}
EUVIMED